Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:AMRN - US0231114044 - ADR

15.29 USD
-0.22 (-1.42%)
Last: 1/21/2026, 8:00:00 PM

AMRN Key Statistics, Chart & Performance

Key Statistics
Market Cap317.92M
Revenue(TTM)226.73M
Net Income(TTM)-86.57M
Shares20.79M
Float1.03M
52 Week High20.9
52 Week Low7.08
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.62
PEN/A
Fwd PE78.9
Earnings (Next)03-10
IPO1993-04-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
AMRN short term performance overview.The bars show the price performance of AMRN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

AMRN long term performance overview.The bars show the price performance of AMRN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of AMRN is 15.29 USD. In the past month the price increased by 10.8%. In the past year, price increased by 21.95%.

AMARIN CORP PLC -ADR / AMRN Daily stock chart

AMRN Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is a bad performer in the overall market: 62.58% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AMRN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AMRN. The financial health of AMRN is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMRN Financial Highlights

Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 65.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -13.12%
ROE -18.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%106.67%
Sales Q2Q%17.43%
EPS 1Y (TTM)65.56%
Revenue 1Y (TTM)-5.93%

AMRN Forecast & Estimates

7 analysts have analysed AMRN and the average price target is 12.24 USD. This implies a price decrease of -19.95% is expected in the next year compared to the current price of 15.29.

For the next year, analysts expect an EPS growth of 56.42% and a revenue growth 6.41% for AMRN


Analysts
Analysts42.86
Price Target12.24 (-19.95%)
EPS Next Y56.42%
Revenue Next Year6.41%

AMRN Ownership

Ownership
Inst Owners20.09%
Ins Owners0.81%
Short Float %40.07%
Short Ratio4.55

About AMRN

Company Profile

AMRN logo image Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Company Info

AMARIN CORP PLC -ADR

WeWork One Central Plaza Dame Street, Dublin 2

DUBLIN Dublin 2 IE

CEO: John F. Thero

Employees: 275

AMRN Company Website

AMRN Investor Relations

Phone: 35316699020

AMARIN CORP PLC -ADR / AMRN FAQ

What does AMRN do?

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.


What is the current price of AMRN stock?

The current stock price of AMRN is 15.29 USD. The price decreased by -1.42% in the last trading session.


What is the dividend status of AMARIN CORP PLC -ADR?

AMRN does not pay a dividend.


What is the ChartMill technical and fundamental rating of AMRN stock?

AMRN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the GICS sector and industry of AMRN stock?

AMARIN CORP PLC -ADR (AMRN) operates in the Health Care sector and the Biotechnology industry.


What is AMARIN CORP PLC -ADR worth?

AMARIN CORP PLC -ADR (AMRN) has a market capitalization of 317.92M USD. This makes AMRN a Small Cap stock.


Can you provide the ownership details for AMRN stock?

You can find the ownership structure of AMARIN CORP PLC -ADR (AMRN) on the Ownership tab.